The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Risk of Nephrogenic Systemic Fibrosis: Evaluation of Gadolinium Chelate Contrast Agents at Four American Universities
Abstract
PURPOSE: To retrospectively determine the benchmark incidence of nephrogenic systemic fibrosis (NSF) related to the confirmed use of different gadolinium chelate contrast agents at four U.S. university tertiary care centers. MATERIALS AND METHODS: Institutional review board approval was obtained for this HIPAA-compliant multi-institutional study; the requirement for informed patient consent was waived. Patients who had a diagnosis of NSF between January 2000 and December 2006 were identified at four tertiary care centers with renal transplant and dialysis services. A standard checklist was used to acquire reliable data from the four centers. The diagnosis of NSF was confirmed histopathologically in all patients. The association of NSF development with gadolinium chelate contrast agent administration in each patient was assessed. The type and cumulative dose of contrast agent administered to each patient with NSF were determined at each center by using the standard checklist. The benchmark incidence of NSF was determined and expressed as the ratio of the number of patients with NSF who had undergone gadolinium chelate-enhanced magnetic resonance (MR) imaging, relative to the total number of patients who underwent gadolinium chelate-enhanced MR imaging at each tertiary care center. Benchmark incidences of NSF were compared among the four centers by using Fisher exact tests. RESULTS: Gadodiamide was used at University of North Carolina at Chapel Hill (center A) and Emory University (center B), and gadopentetate dimeglumine was used at Wake Forest University (center C) and Thomas Jefferson University (center D) during the study period. Twenty-three patients at center A, nine patients at center B, three patients at center C, and one patient at center D had NSF and had undergone gadolinium chelate-enhanced MR imaging. The incidence of NSF was one in 2913 patients who underwent gadodiamide-enhanced MR examinations and one in 44,224 patients who underwent gadopentetate dimeglumine-enhanced MR examinations. CONCLUSION: The benchmark incidence of NSF was much greater at the two centers where gadodiamide was used than at the two centers where gadopentetate dimeglumine was used.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Cited by
Schmidli, J., Widmer, M. K., Basile, C., de Donato, G., Gallieni, M., Gibbons, C. P., Haage, P., Hamilton, G., Hedin, U., Kamper, L., et al. (2018) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2018.02.001 · Cited by 878
Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update
Ramalho, J., Semelka, R. C., Ramalho, M., Nunes, R. H., AlObaidy, M., & Castillo, M. (2016) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4615 · Cited by 453
Self-citationThomsen, H. S., Morcos, S. K., Almén, T., Bellin, M.-F., Bertolotto, M., Bongartz, G., Clement, O., Leander, P., Heinz-Peer, G., Reimer, P., et al. (2013) · European Radiology · doi:10.1007/s00330-012-2597-9 · Cited by 441
Hepatobiliary-specific MR Contrast Agents: Role in Imaging the Liver and Biliary Tree
Seale, M. K., Catalano, O. A., Saini, S., Hahn, P. F., & Sahani, D. V. (2009) · RadioGraphics · doi:10.1148/rg.296095515 · Cited by 388
MRI contrast agents: Basic chemistry and safety
Hao, D., Ai, T., Goerner, F., Hu, X., Runge, V. M., & Tweedle, M. (2012) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.23725 · Cited by 336
Metadata
- Authors
- Wertman, R., Altun, E., Martin, D. R., Mitchell, D. G., Leyendecker, J. R., O'Malley, R. B., Parsons, D. J., Fuller, E. R., & Semelka, R. C.
- Venue
- Radiology
- Published
- 2008-09
- Volume
- 248
- Issue
- 3
- Pages
- 799-806
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2047961324
- Cited by
- 187
- References
- 1
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.